Compare PESI & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PESI | CRBU |
|---|---|---|
| Founded | 1990 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.9M | 203.9M |
| IPO Year | 1992 | 2021 |
| Metric | PESI | CRBU |
|---|---|---|
| Price | $14.62 | $1.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 98.1K | ★ 1.1M |
| Earning Date | 11-10-2025 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $60,661,000.00 | $9,295,000.00 |
| Revenue This Year | $9.91 | $0.22 |
| Revenue Next Year | $62.48 | $4.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.25 | $0.66 |
| 52 Week High | $16.50 | $3.54 |
| Indicator | PESI | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 63.43 | 34.21 |
| Support Level | $14.24 | $1.52 |
| Resistance Level | $14.88 | $1.63 |
| Average True Range (ATR) | 0.61 | 0.08 |
| MACD | 0.15 | -0.00 |
| Stochastic Oscillator | 89.17 | 7.14 |
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: The treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.